640 related articles for article (PubMed ID: 35646659)
1. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers of response to immunotherapy in triple-negative breast cancer - state of the art and future perspectives.
Tancoš V; Blichárová A
Klin Onkol; 2023; 36(1):28-34. PubMed ID: 36868830
[TBL] [Abstract][Full Text] [Related]
3. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
4. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
Qi Y; Yan X; Wang C; Cao H; Liu G
Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
[No Abstract] [Full Text] [Related]
6. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
7. The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.
Buisseret L; Bareche Y; Venet D; Girard E; Gombos A; Emonts P; Majjaj S; Rouas G; Serra M; Debien V; Agostinetto E; Garaud S; Willard-Gallo K; Larsimont D; Stagg J; Rothé F; Sotiriou C
ESMO Open; 2024 May; 9(5):102964. PubMed ID: 38703428
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC?
Zhou Y; Tian Q; Wang BY; Yang J; Zhao SD; Yang J
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2885-2897. PubMed ID: 33877653
[TBL] [Abstract][Full Text] [Related]
10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond.
Rizzo A; Ricci AD
Expert Opin Investig Drugs; 2022 Jun; 31(6):549-555. PubMed ID: 34793275
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido P; Cabal ML; Fernández IP; Pérez YF
Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
[TBL] [Abstract][Full Text] [Related]
13. Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.
Carlino F; Diana A; Piccolo A; Ventriglia A; Bruno V; De Santo I; Letizia O; De Vita F; Daniele B; Ciardiello F; Orditura M
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565233
[TBL] [Abstract][Full Text] [Related]
14. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
16. Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
Uchimiak K; Badowska-Kozakiewicz AM; Sobiborowicz-Sadowska A; Deptała A
Clin Med Insights Oncol; 2022; 16():11795549221099869. PubMed ID: 35721387
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.
Chen X; Feng L; Huang Y; Wu Y; Xie N
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612100
[TBL] [Abstract][Full Text] [Related]
18. Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer.
Tan Q; Chi Y; Su M; Zhou J; Zhou D; Zheng F; Man X; Sun S; Huang J; Li H
Front Genet; 2023; 14():1125970. PubMed ID: 37007962
[No Abstract] [Full Text] [Related]
19. Progress and Challenges of Immunotherapy Predictive Biomarkers for Triple Negative Breast Cancer in the Era of Single-Cell Multi-Omics.
Yu J; Guo Z; Wang L
Life (Basel); 2023 May; 13(5):. PubMed ID: 37240834
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
Yang T; Li W; Huang T; Zhou J
J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]